{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:51:06Z","timestamp":1791417066030,"version":"4.3.3"},"reference-count":106,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011777","name":"Scandinavian Society of Antimicrobial Chemotherapy Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011777","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Tuberculosis and Other Mycobacterial Diseases"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jctube.2026.100645","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:45:25Z","timestamp":1787931925000},"page":"100645","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Macrolide-resistant Mycobacterium avium complex pulmonary disease: A narrative review"],"prefix":"10.1016","volume":"45","author":[{"given":"Yoonis","family":"Cumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina Davies","family":"Forsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Sch\u00f6n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Wejse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Naestholt","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jctube.2026.100645_bb0005","article-title":"British Thoracic Society guideline for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)","volume":"4","author":"Haworth","year":"2017","journal-title":"BMJ Open Respir Res"},{"issue":"1","key":"10.1016\/j.jctube.2026.100645_bb0010","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ccm.2014.10.002","article-title":"Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review","volume":"36","author":"Prevots","year":"2015","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.jctube.2026.100645_bb0015","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ijid.2022.10.013","article-title":"Global trends of pulmonary infections with nontuberculous mycobacteria: a systematic review","volume":"125","author":"Dahl","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"11","key":"10.1016\/j.jctube.2026.100645_bb0020","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1099\/ijsem.0.003026","article-title":"A definition of the Mycobacterium avium complex for taxonomical and clinical purposes, a review","volume":"68","author":"van Ingen","year":"2018","journal-title":"Int J Syst Evol Microbiol"},{"key":"10.1016\/j.jctube.2026.100645_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2025.108055","article-title":"Clinical characteristics and diagnostic practices in nontuberculous mycobacterial pulmonary disease: insights from Denmark","volume":"241","author":"Dahl","year":"2025","journal-title":"Respir Med"},{"key":"10.1016\/j.jctube.2026.100645_bb0030","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12916-016-0606-6","article-title":"\"why me, why now?\" using clinical immunology and epidemiology to explain who gets nontuberculous mycobacterial infection","volume":"14","author":"Lake","year":"2016","journal-title":"BMC Med"},{"issue":"4","key":"10.1016\/j.jctube.2026.100645_bb0035","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ccm.2022.06.010","article-title":"Nontuberculous mycobacterial infections in cystic fibrosis","volume":"43","author":"Martiniano","year":"2022","journal-title":"Clin Chest Med"},{"issue":"11","key":"10.1016\/j.jctube.2026.100645_bb0040","doi-asserted-by":"crossref","first-page":"e1000","DOI":"10.1016\/j.ijid.2013.03.018","article-title":"Non-tuberculous mycobacterial disease is common in patients with non-cystic fibrosis bronchiectasis","volume":"17","author":"Mirsaeidi","year":"2013","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jctube.2026.100645_bb0045","article-title":"Mycobacterium avium complex (MAC) infection in severely immunocompromised people living with HIV: findings from a five-year cohort","author":"Fern\u00e1ndez-D\u00edaz","year":"2024","journal-title":"Int J STD AIDS"},{"issue":"2","key":"10.1016\/j.jctube.2026.100645_bb0050","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.TNMI7-0045-2017","article-title":"Mycobacterium avium complex disease","volume":"5","author":"Daley","year":"2017","journal-title":"Microbiol Spectrum"},{"issue":"1","key":"10.1016\/j.jctube.2026.100645_bb0055","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12879-018-3113-x","article-title":"High mortality in patients with Mycobacterium avium complex lung disease: a systematic review","volume":"18","author":"Diel","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jctube.2026.100645_bb0060","article-title":"Adverse drug reactions during nontuberculous mycobacterial pulmonary disease treatment: a systematic review and meta-analysis","author":"Kim","year":"2025","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"10.1016\/j.jctube.2026.100645_bb0065","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/cid\/ciaa1125","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jctube.2026.100645_bb0070","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1513\/AnnalsATS.201308-266OC","article-title":"Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study","volume":"11","author":"Miwa","year":"2014","journal-title":"Ann Am Thorac Soc"},{"issue":"suppl_2","key":"10.1016\/j.jctube.2026.100645_bb0075","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/jac\/dkx311","article-title":"Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium-intracellulare complex disease","volume":"72","author":"Pasipanodya","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.jctube.2026.100645_bb0080","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1378\/chest.124.4.1482","article-title":"Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine","volume":"124","author":"Field","year":"2003","journal-title":"Chest"},{"issue":"Suppl. 1","key":"10.1016\/j.jctube.2026.100645_bb0085","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/S0924-8579(01)00397-1","article-title":"Comparative safety of the different macrolides","volume":"18","author":"Rubinstein","year":"2001","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"10.1016\/j.jctube.2026.100645_bb0090","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.chest.2018.01.024","article-title":"Microbiologic outcome of interventions against Mycobacterium avium complex pulmonary disease: a systematic review","volume":"153","author":"Diel","year":"2018","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.jctube.2026.100645_bb0095","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/cid\/cix517","article-title":"Treatment outcomes of Mycobacterium avium complex lung disease: a systematic review and Meta-analysis","volume":"65","author":"Kwak","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.jctube.2026.100645_bb0100","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1513\/AnnalsATS.201604-246OC","article-title":"Macrolide-resistant Mycobacterium avium complex lung disease: analysis of 102 consecutive cases","volume":"13","author":"Morimoto","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"11","key":"10.1016\/j.jctube.2026.100645_bb0105","doi-asserted-by":"crossref","first-page":"6758","DOI":"10.1128\/AAC.01240-16","article-title":"Clinical characteristics, treatment outcomes, and resistance mutations associated with macrolide-resistant Mycobacterium avium complex lung disease","volume":"60","author":"Moon","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jctube.2026.100645_bb0110","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s12931-019-1258-9","article-title":"Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium avium complex pulmonary disease: a systematic review and meta-analysis","volume":"20","author":"Park","year":"2019","journal-title":"Respir Res"},{"issue":"1","key":"10.1016\/j.jctube.2026.100645_bb0115","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12890-017-0539-7","article-title":"Implication of species change of nontuberculous mycobacteria during or after treatment","volume":"17","author":"Lee","year":"2017","journal-title":"BMC Pulm Med"},{"issue":"3","key":"10.1016\/j.jctube.2026.100645_bb0120","doi-asserted-by":"crossref","first-page":"467.e9","DOI":"10.1016\/j.cmi.2020.04.020","article-title":"Impact of different subspecies on disease progression in initially untreated patients with Mycobacterium avium complex lung disease","volume":"27","author":"Pan","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.jctube.2026.100645_bb0125","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.01086-25","article-title":"Understanding recurrence in Mycobacterium avium complex pulmonary disease: genotypic strategies to support clinical decision-making","volume":"64","author":"Trinh","year":"2026","journal-title":"J Clin Microbiol"},{"issue":"4","key":"10.1016\/j.jctube.2026.100645_bb0130","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/1040841X.2025.2610213","article-title":"Methods to reduce environmental nontuberculous mycobacteria exposure: revisiting the recent literature","volume":"52","author":"Koch","year":"2026","journal-title":"Crit Rev Microbiol"},{"issue":"7","key":"10.1016\/j.jctube.2026.100645_bb0135","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1164\/rccm.201003-0503OC","article-title":"Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease","volume":"182","author":"Winthrop","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.jctube.2026.100645_bb0140","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/thx.2006.070797","article-title":"Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997 2003","volume":"62","author":"Marras","year":"2007","journal-title":"Thorax"},{"issue":"9","key":"10.1016\/j.jctube.2026.100645_bb0145","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.3201\/eid3009.240095","article-title":"Clinical significance, species distribution, and temporal trends of nontuberculous mycobacteria, Denmark, 1991-2022","volume":"30","author":"Dahl","year":"2024","journal-title":"Emerg Infect Dis"},{"issue":"6","key":"10.1016\/j.jctube.2026.100645_bb0150","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.3904\/kjim.2019.395","article-title":"Age- and sex-related characteristics of the increasing trend of nontuberculous mycobacteria pulmonary disease in a tertiary hospital in South Korea from 2006 to 2016","volume":"35","author":"Park","year":"2020","journal-title":"Korean J Intern Med"},{"issue":"1","key":"10.1016\/j.jctube.2026.100645_bb0155","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00337-2024","article-title":"Laboratory-based surveillance of nontuberculous mycobacterial pulmonary disease in Japan","volume":"11","author":"Hamaguchi","year":"2025","journal-title":"ERJ Open Res"},{"issue":"6","key":"10.1016\/j.jctube.2026.100645_bb0160","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ijantimicag.2009.07.010","article-title":"The role of efflux pumps in macrolide resistance in Mycobacterium avium complex","volume":"34","author":"Rodrigues","year":"2009","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"10.1016\/j.jctube.2026.100645_bb0165","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1128\/AAC.38.2.381","article-title":"Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare","volume":"38","author":"Meier","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.jctube.2026.100645_bb0170","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1128\/AAC.05546-11","article-title":"The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance","volume":"56","author":"Schmalstieg","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.jctube.2026.100645_bb0175","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1164\/rccm.200603-450OC","article-title":"Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease","volume":"174","author":"Griffith","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.jctube.2026.100645_bb0180","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1128\/JCM.00555-13","article-title":"Rapid molecular detection of macrolide resistance in the Mycobacterium avium complex: are we there yet?","volume":"51","author":"Christianson","year":"2013","journal-title":"J Clin Microbiol"},{"issue":"4","key":"10.1016\/j.jctube.2026.100645_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2024.116526","article-title":"Evaluation of the GenoType NTM-DR line probe assay for nontuberculous mycobacteria using whole genome sequences as reference standard","volume":"110","author":"Epperson","year":"2024","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"8","key":"10.1016\/j.jctube.2026.100645_bb0190","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00516-19","article-title":"GenoType NTM-DR performance evaluation for identification of Mycobacterium avium complex and Mycobacterium abscessus and determination of clarithromycin and amikacin resistance","volume":"57","author":"Huh","year":"2019","journal-title":"J Clin Microbiol"},{"issue":"6","key":"10.1016\/j.jctube.2026.100645_bb0195","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1093\/jac\/dkx021","article-title":"Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria","volume":"72","author":"Mougari","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.jctube.2026.100645_bb0200","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1128\/JCM.02954-15","article-title":"PCR-based rapid identification system using bridged nucleic acids for detection of clarithromycin-resistant Mycobacterium avium-M. Intracellulare complex isolates","volume":"54","author":"Hirama","year":"2016","journal-title":"J Clin Microbiol"},{"issue":"1","key":"10.1016\/j.jctube.2026.100645_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1054\/tuld.1999.0227","article-title":"Molecular basis of clarithromycin-resistance in Mycobacterium avium intracellulare complex","volume":"80","author":"Jamal","year":"2000","journal-title":"Tuber Lung Dis"},{"issue":"5","key":"10.1016\/j.jctube.2026.100645_bb0210","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1469-0691.2010.03307.x","article-title":"Mycobacterium avium ssp. hominissuis biofilm is composed of distinct phenotypes and influenced by the presence of antimicrobials","volume":"17","author":"McNabe","year":"2011","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"10.1016\/j.jctube.2026.100645_bb0215","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1128\/AAC.48.12.4907-4910.2004","article-title":"A subinhibitory concentration of clarithromycin inhibits Mycobacterium avium biofilm formation","volume":"48","author":"Carter","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.jctube.2026.100645_bb0220","doi-asserted-by":"crossref","DOI":"10.1099\/jmm.0.002072","article-title":"A viable but nonculturable state of Mycobacterium avium in response to macrolide antibiotics: a recipe for relapses?","volume":"74","author":"Schuiermanni","year":"2025","journal-title":"J Med Microbiol"},{"issue":"4","key":"10.1016\/j.jctube.2026.100645_bb0225","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.jctube.2026.100645_bb0230","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1128\/JCM.42.5.2321-2325.2004","article-title":"Meta-analysis of BACTEC MGIT 960 and BACTEC 460 TB, with or without solid media, for detection of mycobacteria","volume":"42","author":"Cruciani","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jctube.2026.100645_bb0235","series-title":"CLSI standards: guidelines for health care excellence","article-title":"susceptibility testing of mycobacteria, Nocardiae, and other aerobic actinomycetes","author":"Woods","year":"2011"},{"issue":"6","key":"10.1016\/j.jctube.2026.100645_bb0240","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.cmi.2023.02.007","article-title":"Towards clinical breakpoints for non-tuberculous mycobacteria - determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution","volume":"29","author":"Fr\u00f6berg","year":"2023","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.jctube.2026.100645_bb0245","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1128\/CMR.05030-11","article-title":"Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria","volume":"25","author":"Brown-Elliott","year":"2012","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"10.1016\/j.jctube.2026.100645_bb0250","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cmi.2016.10.022","article-title":"Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives","volume":"23","author":"Sch\u00f6n","year":"2017","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.jctube.2026.100645_bb0255","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41598-021-81025-w","article-title":"First line treatment selection modifies disease course and long-term clinical outcomes in Mycobacterium avium complex pulmonary disease","volume":"11","author":"Fukushima","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jctube.2026.100645_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106025","article-title":"Macrolide resistant Mycobacterium avium complex pulmonary disease following clarithromycin and ethambutol combination therapy","volume":"169","author":"Ito","year":"2020","journal-title":"Respir Med"},{"issue":"12","key":"10.1016\/j.jctube.2026.100645_bb0265","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1093\/jac\/dkad317","article-title":"In vitro susceptibility patterns for slowly growing non-tuberculous mycobacteria in the USA from 2018 to 2022","volume":"78","author":"Calado Nogueira de Moura","year":"2023","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.jctube.2026.100645_bb0270","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jiac.2017.10.022","article-title":"Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens","volume":"24","author":"Cho","year":"2018","journal-title":"J Infect Chemother"},{"issue":"2","key":"10.1016\/j.jctube.2026.100645_bb0275","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijantimicag.2009.09.023","article-title":"In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in the Netherlands","volume":"35","author":"van Ingen","year":"2010","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"10.1016\/j.jctube.2026.100645_bb0280","first-page":"77","article-title":"Underutilization of nontuberculous mycobacterial drug susceptibility testing in Ontario, Canada, 2010-2015","volume":"5","author":"Andrews","year":"2020","journal-title":"J Assoc Med Microbiol Infect Dis Can"},{"issue":"12","key":"10.1016\/j.jctube.2026.100645_bb0285","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms12122613","article-title":"Susceptibility patterns in clinical isolates of Mycobacterium avium complex from a Hospital in Southern Spain","volume":"12","author":"Gonz\u00e1lez Mart\u00ednez","year":"2024","journal-title":"Microorganisms"},{"issue":"8","key":"10.1016\/j.jctube.2026.100645_bb0290","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms12081615","article-title":"The drug susceptibility of non-tuberculous mycobacteria (NTM) in a referral hospital in Rome from 2018 to 2023","volume":"12","author":"Mazzarelli","year":"2024","journal-title":"Microorganisms"},{"key":"10.1016\/j.jctube.2026.100645_bb0295","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jgar.2022.05.027","article-title":"Identification and drug susceptibility testing of the subspecies of Mycobacterium avium complex clinical isolates in mainland China","volume":"31","author":"Li","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"issue":"2","key":"10.1016\/j.jctube.2026.100645_bb0300","doi-asserted-by":"crossref","first-page":"182","DOI":"10.7705\/biomedica.7197","article-title":"Prevalence of resistance to macrolides and aminoglycosides in Mycobacterium avium, M. abscessus, and M. chelonae identified in the Laboratorio Nacional de Referencia of Colombia from 2018 to 2022","volume":"44","author":"Llerena","year":"2024","journal-title":"Biomedica"},{"key":"10.1016\/j.jctube.2026.100645_bb0305","series-title":"susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes","author":"Clinical and laboratory standards institute (CLSI)","year":"2018"},{"key":"10.1016\/j.jctube.2026.100645_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107366","article-title":"Monotherapy: key cause of macrolide-resistant Mycobacterium avium complex disease","volume":"217","author":"Loewenstein","year":"2023","journal-title":"Respir Med"},{"key":"10.1016\/j.jctube.2026.100645_bb0315","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12879-016-1384-7","article-title":"Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease","volume":"16","author":"Kadota","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.jctube.2026.100645_bb0320","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1164\/rccm.201408-1545OC","article-title":"Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease","volume":"191","author":"Jeong","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.jctube.2026.100645_bb0325","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1378\/chest.13-2538","article-title":"Macrolide\/azalide therapy for nodular\/bronchiectatic mycobacterium avium complex lung disease","volume":"146","author":"Wallace","year":"2014","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.jctube.2026.100645_bb0330","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.chest.2021.02.019","article-title":"The Association of Long-term Macrolide Therapy and Nontuberculous Mycobacterial Culture Positivity in patients with bronchiectasis","volume":"160","author":"Metersky","year":"2021","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.jctube.2026.100645_bb0335","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01787-19","article-title":"Intermittent treatment with azithromycin and ethambutol for noncavitary Mycobacterium avium complex pulmonary disease","volume":"64","author":"Moon","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jctube.2026.100645_bb0340","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12866-022-02582-2","article-title":"In vitro assessment of 17 antimicrobial agents against clinical Mycobacterium avium complex isolates","volume":"22","author":"Lin","year":"2022","journal-title":"BMC Microbiol"},{"issue":"5","key":"10.1016\/j.jctube.2026.100645_bb0345","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02210-2023","article-title":"Rifampicin has no role in treatment of Mycobacterium avium complex pulmonary disease and bactericidal sterilising drugs are needed: a viewpoint","volume":"63","author":"van Ingen","year":"2024","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.jctube.2026.100645_bb0350","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00610-2023","article-title":"Mycobacterium avium complex pulmonary disease patients with limited treatment options","volume":"10","author":"Aliberti","year":"2024","journal-title":"ERJ Open Res"},{"issue":"4","key":"10.1016\/j.jctube.2026.100645_bb0355","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.ccm.2023.06.009","article-title":"Treatment of Mycobacterium avium complex pulmonary disease: when should I treat and what therapy should I start?","volume":"44","author":"Nguyen","year":"2023","journal-title":"Clin Chest Med"},{"issue":"4","key":"10.1016\/j.jctube.2026.100645_bb0360","doi-asserted-by":"crossref","first-page":"212","DOI":"10.5588\/ijtld.23.0551","article-title":"Advantages and limitations of virtual multi-disciplinary team meetings on difficult-to-treat mycobacteria","volume":"28","author":"Dahl","year":"2024","journal-title":"Int J Tuberc Lung Dis"},{"issue":"11","key":"10.1016\/j.jctube.2026.100645_bb0365","doi-asserted-by":"crossref","first-page":"e0121324","DOI":"10.1128\/aac.01213-24","article-title":"Variability of macrolide-resistant profile in Mycobacterium avium complex pulmonary disease","volume":"68","author":"Fukushima","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.jctube.2026.100645_bb0370","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1093\/cid\/ciae421","article-title":"Nontuberculous mycobacterial pulmonary disease: patients, principles, and prospects","volume":"79","author":"Nguyen","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jctube.2026.100645_bb0375","article-title":"Consensus on management of refractory nontuberculous mycobacterial pulmonary disease","author":"Moreira-Sousa","year":"2025","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.jctube.2026.100645_bb0380","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02261-21","article-title":"Treatment outcomes of cavitary nodular Bronchiectatic-type Mycobacterium avium complex pulmonary disease","volume":"66","author":"Chae","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.jctube.2026.100645_bb0385","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.chest.2024.10.010","article-title":"Isolation of genetically distinct strains within the same species during treatment of Mycobacterium avium complex pulmonary disease","volume":"167","author":"Lee","year":"2025","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.jctube.2026.100645_bb0390","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jiac.2020.02.008","article-title":"Effective treatment for clarithromycin-resistant Mycobacterium avium complex lung disease","volume":"26","author":"Adachi","year":"2020","journal-title":"J Infect Chemother"},{"issue":"11","key":"10.1016\/j.jctube.2026.100645_bb0395","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1086\/420742","article-title":"Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases","volume":"38","author":"Peloquin","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.jctube.2026.100645_bb0400","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","article-title":"Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT). A prospective, open-label, randomized study","volume":"198","author":"Griffith","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.jctube.2026.100645_bb0405","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4046\/trd.2023.0120","article-title":"Real-world outcomes of amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease","volume":"87","author":"Kim","year":"2024","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"10.1016\/j.jctube.2026.100645_bb0410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rmed.2018.07.003","article-title":"Adjuvant lung resection in the management of nontuberculous mycobacterial lung infection: a retrospective matched cohort study","volume":"142","author":"Aznar","year":"2018","journal-title":"Respir Med"},{"issue":"suppl_2","key":"10.1016\/j.jctube.2026.100645_bb0415","doi-asserted-by":"crossref","first-page":"i24","DOI":"10.1093\/jac\/dkx304","article-title":"Linezolid as treatment for pulmonary Mycobacterium avium disease","volume":"72","author":"Deshpande","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.jctube.2026.100645_bb0420","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1183\/09031936.00169114","article-title":"The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease","volume":"45","author":"Winthrop","year":"2015","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.jctube.2026.100645_bb0425","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1128\/JCM.00274-17","article-title":"In vitro susceptibility testing of tedizolid against nontuberculous mycobacteria","volume":"55","author":"Brown-Elliott","year":"2017","journal-title":"J Clin Microbiol"},{"issue":"3","key":"10.1016\/j.jctube.2026.100645_bb0430","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01157-23","article-title":"Clofazimine as a substitute for rifampicin improves efficacy of Mycobacterium avium pulmonary disease treatment in the hollow-fiber model","volume":"68","author":"Salillas","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.jctube.2026.100645_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107423","article-title":"Replacing rifampicin with minocycline increases the activity of the treatment regimen for Mycobacterium avium complex pulmonary disease in a dynamic hollow-fibre system","volume":"65","author":"Raaijmakers","year":"2025","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.jctube.2026.100645_bb0440","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004143","article-title":"Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies","volume":"4","author":"Hwang","year":"2014","journal-title":"BMJ Open"},{"issue":"10","key":"10.1016\/j.jctube.2026.100645_bb0445","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1586\/14787210.2013.830413","article-title":"Drug treatment of pulmonary nontuberculous mycobacterial disease in HIV-negative patients: the evidence","volume":"11","author":"van Ingen","year":"2013","journal-title":"Expert Rev Anti-Infect Ther"},{"issue":"2","key":"10.1016\/j.jctube.2026.100645_bb0450","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1128\/AAC.02615-15","article-title":"Clofazimine prevents the regrowth of Mycobacterium abscessus and Mycobacterium avium type strains exposed to amikacin and clarithromycin","volume":"60","author":"Ferro","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.jctube.2026.100645_bb0455","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.chest.2023.11.038","article-title":"Safety and efficacy of clofazimine as an alternative for rifampicin in Mycobacterium avium complex pulmonary disease treatment: outcomes of a randomized trial","volume":"165","author":"Zweijpfenning","year":"2024","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.jctube.2026.100645_bb0460","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01853-24","article-title":"The efficacy of a regimen comprising clarithromycin, clofazimine, and bedaquiline in a mouse model of chronic Mycobacterium avium lung infection","volume":"69","author":"Rimal","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.jctube.2026.100645_bb0465","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1164\/rccm.201402-0385CI","article-title":"Macrolide antibiotics and the risk of cardiac arrhythmias","volume":"189","author":"Albert","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.jctube.2026.100645_bb0470","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1093\/jac\/dkaa310","article-title":"Clofazimine pharmacokinetics in patients with TB: dosing implications","volume":"75","author":"Abdelwahab","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jctube.2026.100645_bb0475","article-title":"Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California","volume":"23","author":"Katrak","year":"2021","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"issue":"2","key":"10.1016\/j.jctube.2026.100645_bb0480","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01798-16","article-title":"In vitro susceptibility testing of Bedaquiline against Mycobacterium avium complex","volume":"61","author":"Brown-Elliott","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jctube.2026.100645_bb0485","first-page":"58","article-title":"Bedaquiline does not enhance clofazimine treatment efficacy with an azithromycin-ethambutol backbone against Mycobacterium avium in a hollow fibre system","volume":"39","author":"Raaijmakers","year":"2024","journal-title":"J Global Antimicrobial Resistance"},{"issue":"2","key":"10.1016\/j.jctube.2026.100645_bb0490","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1378\/chest.14-2764","article-title":"Preliminary results of Bedaquiline as salvage therapy for patients with nontuberculous mycobacterial lung disease","volume":"148","author":"Philley","year":"2015","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.jctube.2026.100645_bb0495","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/jac\/dkac068","article-title":"Omadacycline efficacy in the hollow fibre system model of pulmonary Mycobacterium avium complex and potency at clinically attainable doses","volume":"77","author":"Chapagain","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.jctube.2026.100645_bb0500","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00917-23","article-title":"Mavintramycin a is a promising antibiotic for treating Mycobacterium avium complex infectious disease","volume":"68","author":"Hosoda","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 2","key":"10.1016\/j.jctube.2026.100645_bb0505","first-page":"655","article-title":"Epetraborole, a novel bacterial leucyl-tRNA synthetase inhibitor, demonstrates potent efficacy and improves efficacy of a standard of care regimen against Mycobacterium avium complex in a chronic mouse lung infection model","volume":"9","author":"De","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"10.1016\/j.jctube.2026.100645_bb0510","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/jac\/dkae046","article-title":"Efficacy of SPR720 in murine models of non-tuberculous mycobacterial pulmonary infection","volume":"79","author":"Cotroneo","year":"2024","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"10.1016\/j.jctube.2026.100645_bb0515","doi-asserted-by":"crossref","first-page":"e0120821","DOI":"10.1128\/AAC.01208-21","article-title":"First-in-human evaluation of the safety, tolerability, and pharmacokinetics of SPR720, a novel oral bacterial DNA gyrase (GyrB) inhibitor for mycobacterial infections","volume":"65","author":"Talley","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jctube.2026.100645_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115539","article-title":"Clofazimine: a journey of a drug","volume":"167","author":"Xu","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"10.1016\/j.jctube.2026.100645_bb0525","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad682","article-title":"Treatment outcomes of clofazimine-containing regimens in severe Mycobacterium avium complex pulmonary disease","volume":"11","author":"Lee","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jctube.2026.100645_bb0530","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jgar.2020.01.022","article-title":"Minocycline, focus on mechanisms of resistance, antibacterial activity, and clinical effectiveness: Back to the future","volume":"22","author":"Asadi","year":"2020","journal-title":"J Glob Antimicrob Resist"}],"container-title":["Journal of Clinical Tuberculosis and Other Mycobacterial Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405579426000677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405579426000677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:14:01Z","timestamp":1791414841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405579426000677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":106,"alternative-id":["S2405579426000677"],"URL":"https:\/\/doi.org\/10.1016\/j.jctube.2026.100645","relation":{},"ISSN":["2405-5794"],"issn-type":[{"value":"2405-5794","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Macrolide-resistant Mycobacterium avium complex pulmonary disease: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jctube.2026.100645","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100645"}}